SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    W L Kuan, A Kasis, Y Yuan, S L Mason, A S Lazar, R A Barker, J Goncalves, Modelling the natural history of Huntington's disease progression, Journal of Neurology, Neurosurgery & Psychiatry, 2015, 86, 10, 1143

    CrossRef

  2. 2
    K Fink, A Crane, J Rossignol, L Lescaudron, G Dunbar, Stem Cells and Neurodegenerative Diseases, 2014,

    CrossRef

  3. 3
    Christian Beste, Ann-Kathrin Stock, Vanessa Ness, Rainer Hoffmann, Carsten Lukas, Carsten Saft, A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data, Scientific Reports, 2013, 3,

    CrossRef

  4. 4
    Laurie K. Mischley, Jason Allen, Ryan Bradley, Coenzyme Q10 deficiency in patients with Parkinson's disease, Journal of the Neurological Sciences, 2012, 318, 1-2, 72

    CrossRef

  5. 5
    M.P. Zanin, L.N. Pettingill, A.R. Harvey, D.F. Emerich, C.G. Thanos, R.K. Shepherd, The development of encapsulated cell technologies as therapies for neurological and sensory diseases, Journal of Controlled Release, 2012, 160, 1, 3

    CrossRef

  6. 6
    Michael R. MacAskill, Charlotte F. Graham, Toni L. Pitcher, Daniel J. Myall, Leslie Livingston, Saskia van Stockum, John C. Dalrymple-Alford, Tim J. Anderson, The influence of motor and cognitive impairment upon visually-guided saccades in Parkinson's disease, Neuropsychologia, 2012, 50, 14, 3338

    CrossRef

  7. 7
    Jonathan R. Evans, Sarah L. Mason, Roger A. Barker, Functional Neural Transplantation III - Primary and Stem Cell Therapies for Brain Repair, Part I, 2012,

    CrossRef

  8. 8
    Min Shi, Joshua Bradner, Aneeka M. Hancock, Kathryn A. Chung, Joseph F. Quinn, Elaine R. Peskind, Douglas Galasko, Joseph Jankovic, Cyrus P. Zabetian, Hojoong M. Kim, James B. Leverenz, Thomas J. Montine, Carmen Ginghina, Un Jung Kang, Kevin C. Cain, Yu Wang, Jan Aasly, David Goldstein, Jing Zhang, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Annals of Neurology, 2011, 69, 3
  9. 9
    David P. Breen, Andrew W. Michell, Roger A. Barker, Parkinson's disease – the continuing search for biomarkers, Clinical Chemistry and Laboratory Medicine, 2011, 49, 3

    CrossRef

  10. 10
    C. Gibrat, F. Cicchetti, Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 2, 380

    CrossRef

  11. 11
    Trevor Archer, Richard M. Kostrzewa, Richard J. Beninger, Tomas Palomo, Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions, Neurotoxicity Research, 2011, 19, 2, 211

    CrossRef

  12. 12
    Adriane Gröger, Grzegorz Chadzynski, Jana Godau, Daniela Berg, Uwe Klose, Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson’s disease, European Radiology, 2011, 21, 9, 1962

    CrossRef

  13. 13
    John P. Seibyl, SPECT and PET in Atypical Parkinsonism, PET Clinics, 2010, 5, 1, 65

    CrossRef

  14. 14
    Elisabeth A Lloyd, Sean Valles, Behavioural Phenotypes: Goals and Methods, eLS,